Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Food Sci Technol ; 59(1): 144-156, 2022 Jan.
Article in English | MEDLINE | ID: mdl-35068559

ABSTRACT

Blend films with poly(ε-caprolactone)(PCL) and poly(propylene carbonate)(PPC)with thickness of approximately 40 µm and 60 µm, respectively, were prepared using a uniaxial-stretching extrusion process to modify the property of PCL. PCL/PPC blend films with better comprehensive properties with thickness about 60 µm were used for equilibrium-modified atmosphere packaging of button mushrooms at 5 °C. The gas barrier property together with water vapor permeability were evaluated as well as its effects on the shelf life button mushrooms. The results showed that the PCL/PPC20 and PCL/PPC50 blend films have suitable gas barrier property and water vapor permeability, which was helpful to generate an appropriate storage environment and more importantly no condensation occurred in these two packages. The lower weight loss of button mushrooms was observed for PCL/PPC20 and PCL/PPC50 blend films 4.43 and 4.46, respectively. The PCL/PPC blend films was more effective in decreasing the activity of PPO and preserving the color of the button mushrooms. The over market acceptability of button mushrooms packaged in PCL/PPC blend films still maintained good and within the limit of marketability after 17 days of storage.

2.
World J Gastroenterol ; 11(7): 954-9, 2005 Feb 21.
Article in English | MEDLINE | ID: mdl-15742395

ABSTRACT

AIM: To investigate the possibility of recombinant high-density lipoprotein (rHDL) being a carrier for delivering antitumoral drug to hepatoma cells. METHODS: Recombinant complex of HDL and aclacinomycin (rHDL-ACM) was prepared by cosonication of apoproteins from HDL (Apo HDL) and ACM as well as phosphatidylcholine. Characteristics of the rHDL-ACM were elucidated by electrophoretic mobility, including the size of particles, morphology and entrapment efficiency. Binding activity of rHDL-ACM to human hepatoma cells was determined by competition assay in the presence of excess native HDL. The cytotoxicity of rHDL-ACM was assessed by MTT method. RESULTS: The density range of rHDL-ACM was 1.063-1.210 g/mL, and the same as that of native HDL. The purity of all rHDL-ACM preparations was more than 92%. Encapsulated efficiencies of rHDL-ACM were more than 90%. rHDL-ACM particles were typical sphere model of lipoproteins and heterogeneous in particle size. The average diameter was 31.26+/-5.62 nm by measure of 110 rHDL-ACM particles in the range of diameter of lipoproteins. rHDL-ACM could bind on SMMC-7721 cells, and such binding could be competed against in the presence of excess native HDL. rHDL-ACM had same binding capacity as native HDL. The cellular uptake of rHDL-ACM by SMMC-7721 hepatoma cells was significantly higher than that of free ACM at the concentration range of 0.5-10 microg/mL (P<0.01). Cytotoxicity of rHDL-ACM to SMMC-7721 cells was significantly higher than that of free ACM at concentration range of less than 5 microg/mL (P<0.01) and IC50 of rHDL-ACM was lower than IC50 of free ACM (1.68 nmol/L vs 3 nmol/L). Compared to L02 hepatocytes, a normal liver cell line, the cellular uptake of rHDL-ACM by SMMC-7721 cells was significantly higher (P<0.01) and in a dose-dependent manner at the concentration range of 0.5-10 microg/mL. Cytotoxicity of the rHDL-ACM to SMMC-7721 cells was significantly higher than that to L02 cells at concentration range of 1-7.5 microg/mL (P<0.01). IC50 for SMMC-7721 cells (1.68 nmol/L) was lower than that for L02 cells (5.68 nmol/L), showing a preferential cytotoxicity of rHDL-ACM for SMMC-7721 cells. CONCLUSION: rHDL-ACM complex keeps the basic physical and biological binding properties of native HDL and shows a preferential cytotoxicity for SMMC-7721 hepatoma to normal L02 hepatocytes. HDL is a potential carrier for delivering lipophilic antitumoral drug to hepatoma cells.


Subject(s)
Aclarubicin/analogs & derivatives , Aclarubicin/pharmacokinetics , Antibiotics, Antineoplastic/pharmacokinetics , Carcinoma, Hepatocellular , Drug Carriers/pharmacokinetics , Lipoproteins, HDL/pharmacokinetics , Liver Neoplasms , Cell Line, Tumor , Hepatocytes/cytology , Hepatocytes/drug effects , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...